logo-loader
HealthPharma & Biotech
Silence Therapeutics PLC

Silence Therapeutics makes key new hire

Giles Campion has been appointed head of research and development and chief medical officer

1555398588_rsz_shutterstock_178464512.jpg
Chief executive David Horn Solomon said Campion would be a valuable addition to the management team

Silence Therapeutics PLC (LON:SLN) has appointed industry veteran Giles Campion as head of research and development and the company’s chief medical officer.

He occupied the same roles at Prosensa, which was acquired by Biomarin in 2015 for US$680mln and, in his 20-year career, he also held senior R&D roles at the Swiss giant Novartis (NYSE:NVS). He holds a medical degree and doctorate from Bristol University.

READ: Silence Therapeutics makes clinical trial application for lead drug

“Giles is a valuable addition to the management team and his expertise will help the company to deliver on its core mission of tackling the unmet medical needs of patients suffering from rare conditions," said Silence chief executive David Horn Solomon.

Campion joins the company on June 1

In a later announcement, Silence also said the search for a permanent chairman continues after announcing that interim chair, Dr Andy Richards, had stepped down with immediate effect.

 -- Adds chairman's departure --

Quick facts: Silence Therapeutics PLC

Price: £2.40

Market: AIM
Market Cap: £187.43 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Silence Therapeutics PLC named herein, including the promotion by the Company of Silence Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Silence Therapeutics 'in a hot space with few competitors'

Silence Therapeutics' (LON:SLN) executive chair Annalisa Jenkins sat down with Proactive's Andrew Scott to discuss her strategy for taking the drug developer forward and the 'exciting opportunities' in the RNAi space. On what attracted Jenkins to join Silence, she says: ''The opportunity...

on 12/6/18

RNS

Additional Listing

2 days, 4 hours ago

Holding(s) in Company

3 weeks, 2 days ago

Additional Listing

4 weeks, 1 day ago

Additional Listing

on 20/8/19

Additional Listing

on 13/8/19

Additional Listing

on 9/8/19

2 min read